Is there a role for bevacizumab in the treatment of glioblastoma?

Oncologist

Volumn 18, Issue 10, 2013, Pages 1080-1082

  Chi, Andrew S ^a   Chamberlain, Marc C ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ARTICLE; CANCER INCIDENCE; DNA METHYLATION; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLFACTORY HALLUCINATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; BRAIN NEOPLASMS; CASE REPORT; DISEASE FREE SURVIVAL; MALE; MIDDLE AGED; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84886045219     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0296     Document Type: Article

References (20)

1. FriedmanHS, PradosMD, WenPYetal. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740.
2. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
3. Gilbert M, Dignam J, WonMet al. RTOG0825: Phase III double-blind placebocontrolled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013;31(suppl):abstract 01.
4. Chinot O, Wick W, MasonWet al: Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: Mature progression-free survival and preliminary overall survival results in AVAglio. Neuro-Oncol 2012;14(suppl):abstract OT-03.
5. Henriksson R, Bottomley A, MasonWet al. Progression free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase 3 study of bevacizumab(Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 2013;31(suppl):abstract 2005.
6. Armstrong T, Won M, Wefel JS et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. J Clin Oncol 2013;31(suppl):abstract 2003.
7. Wefel JS, Pugh SL, Armstrong T et al. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled inRTOG0825. J Clin Oncol 2013;31(suppl):abstract 2004.
8. KamounWS, LeyCD, FarrarCTet al. Edemacontrolbycediranib, avascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009;27:2542-2552.
9. Lou E, Peters KB, Sumrall AL et al. Phase II trial of upfront bevacizumabandtemozolomideforunresectableor multifocal glioblastoma. CancerMed2013;2:185-195.
10. Taal W, Oosterkamp HM, Walenkamp AME et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 2013;31(suppl):abstract 2001.
11. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-4740.
12. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
13. Field KM, Simes J, Wheeler H et al. A randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). J Clin Oncol 2013;31(suppl):abstract 2017.
14. Taal W, Oosterkamp HM, Walenkamp AME et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 2013;31(suppl):abstract 2001.
15. GilbertM, DignamJ, WonMet al. RTOG0825:Phase3double blind placebo controlled trial evaluating bevacizumab (BEV) in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2013;31(suppl):abstract 01.
16. WickW, Cloughesy T, Nishikawa R et al. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase 3 AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 3013;31(suppl):abstract 2002.
17. Reyes-Botero G, Honnorat J, Chinot O et al. Temozolomide plus bevacizumab in elderly patients with newly diagnosed and poor performance status: An ANOCEF phase 2 trial. J Clin Oncol 2013;31(suppl):abstract 2020.
18. Armstrong T, Won M, Wefel JS et al. Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825. J Clin Oncol 2013;31(suppl):abstract 2003.
19. Wefel JS, Pugh SL, Armstrong T et al. Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled inRTOG0825. J Clin Oncol 2013;31(suppl):abstract 2004.
20. Henriksson R, Bottomley A, MasonWet al. Progression free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase 3 study of bevacizumab(Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 2013;31(suppl):abstract 2005.